AstraZeneca + Saint Luke’s Mid America Heart Institute initiate phase III DARE-19 trial with Farxiga in COVID-19 patients.
AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients… read more.